Analysis

Zymeworks Inc. (ZYME) Stock Analysis

Zymeworks Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to ZYME.

websiteZYME/analysis/ZYME

Zymeworks Inc.

Zymeworks Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to ZYME.

Stock profile

Ticker

ZYME

Asset type

Stock

Market cap

$1.70B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Zymeworks Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • ZYME primary listing
  • ZA8
  • A3DSSN

Latest Zymeworks Inc. news

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

Gandeeva Therapeutics, Inc., a biotech at the forefront of cryo-electron microscopy (cryo-EM)–driven drug design, and Zymeworks Inc. (Nasdaq: ZYME), a global biotechnology compa...

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while dev...

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally adv...

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expressionConfirmed objective

Research sections

Valuation

Review valuation context for Zymeworks Inc..

Future growth

Review future growth context for Zymeworks Inc..

Past performance

Review past performance context for Zymeworks Inc..

Financial health

Review financial health context for Zymeworks Inc..

Dividend

Review dividend context for Zymeworks Inc..

Management

Review management context for Zymeworks Inc..

Ownership

Review ownership context for Zymeworks Inc..

Other information

Review other information context for Zymeworks Inc..

Community

Review community context for Zymeworks Inc..